On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease. Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease. Having already prescribed the treatment to real-life patients, Dr. Robert Przybelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system.
Guest: Robert Przybelski, MD, MS, director, Geriatric Memory Clinics, UW Health, professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health
Show NotesRead more about Lecanemab’s Appropriate Use Guidelines on our website.
Read the FDA’s press release, “FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval.”
Listen to previous Dementia Matters episodes on lecanemab, “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” and “A Closer Look at the Lecanemab Clinical Trials,” on our website and all major podcast platforms.
Listen to Dr. Przybelski’s previous episode of Dementia Matters, “Vitamin Deficiency And Its Impact On Brain Health,” on our website, Spotify, Apple Podcasts, Podbean, and all major podcast platforms.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Making an IMPACT: Advancing Alzheimer’s Disease Clinical Trials Through Workforce Development and Inclusivity
Living with Lewy Body: A Neurologist’s Journey Through Research and Dementia Care
The Fundamentals of Neuropsychology: Breaking Down Cognition, Memory and More
Long COVID and Its Effect on Cognition
Listen Up! The Connections Between Hearing Loss, Hearing Interventions and Cognitive Decline
From Caregiver to Research Participant: How One Woman’s Experience as a Dementia Caregiver Drew Her to Alzheimer’s Research
Looking at Lecanemab’s Eligibility Guidelines and Prescription Process
Do Non-Medicinal Interventions Reduce Dementia Risk? Studies are Inconclusive, Here’s Why
The Road to Hope: Philanthropy’s Impact on Alzheimer’s Research
Could Green Tea Hold the Key to New Alzheimer’s Treatments?
The Impact of Social Isolation on Dementia Risk in Older Adults
Memories and Milestones: Celebrating Six Years of ‘Dementia Matters’
Crosswords or Computers: Which is Better for Cognitive Engagement?
RAISE(ing) Support for Caregivers: State and National Resources for Family Care Partners
Mental Health and Memory: The Connections between Chronic Mental Illness and Dementia
Highlights from the 2023 Alzheimer’s Association International Conference
A Fair Fight Against Alzheimer’s: The Need for Equity in Dementia Research and Care
Agitation and Alzheimer’s: Strategies for Managing Behavioral and Psychological Symptoms of Dementia
Promises to Practice: Creating Sustainable Community Partnerships to Support Alzheimer’s Research
Study Shows APOE Gene Affects Hispanic Populations’ Risk of Cognitive Decline Differently to Non-Hispanic Populations
Create your
podcast in
minutes
It is Free
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks